



13 Approvals

We have reviewed this study protocol (ER-9502 Version 1.0, dated 02 April 2015) and agree to its terms by signing it.

Principal investigator:



Signature

Date

Tuire Prami

EPID Research, Metsänneidonkuja 12, FI-02130 Espoo

Medical experts of the scientific committee:

Signature

Date

Juhani Airaksinen

Turku University Hospital, P.O. Box 52 FI-20521 Turku

Signature

Date

Eeva Reissell

THL, P.O. Box 30 FI-00271 Helsinki

Signature

Date

Ville Kytö

Turku University Hospital, P.O. Box 52 FI-20521 Turku

On behalf of the sponsor:

Signature

Date

Susanne Skovgaard Nickelsen, MD VP Medical/Regularory AstraZeneca Nordic-Baltic

Medical Nordic-Baltic, AstraZeneca Nordic-Baltic, Arne Jacobsens Allé 13 DK-2300 Copenhagen S Denmark

13 Approvals

We have reviewed this study protocol (ER-9502 Version 1.0, dated 02 April 2015) and agree to its terms by signing it.

Principal investigator:

Signature

Date

Tuire Prami

EPID Research, Metsänneidonkuja 12, FI-02130 Espoo

Medical experts of the scientific committee:

Signature

Date

Juhani Airaksinen

Turku University Hospital, P.O. Box 52 FI-20521 Turku

Signature

Date

Eeva Reissell

THL, P.O. Box 30 FI-00271 Helsinki

Signature

Date

Ville Kytö

Turku University Hospital, P.O. Box 52 FI-20521 Turku

On behalf of the sponsor:

Signature

Date

Susanne Skovgaard Nickelsen, MD VP Medical/Regularory AstraZeneca Nordic-Baltic

Medical Nordic-Baltic, AstraZeneca Nordic-Baltic, Arne Jacobsens Allé 13 DK-2300 Copenhagen S Denmark

13 Approvals

We have reviewed this study protocol (ER-9502 Version 1.0, dated 02 April 2015) and agree to its terms by signing it:

Principal investigator:

Signature

Date

Tuire Prami

EPID Research, Metsänneidonkuja 12, FI-02130 Espoo

Medical experts of the scientific committee:

Signature

Date

Juhani Airaksinen

Turku University Hospital, P.O. Box 52 FI-20521 Turku



13.4.2015

Signature

Date

Eeva Reissell

THL, P.O. Box 30 FI-00271 Helsinki

Signature

Date

Ville Kytö

Turku University Hospital, P.O. Box 52 FI-20521 Turku

On behalf of the sponsor:

Signature

Date

Susanne Skovgaard Nickelsen, MD VP Medical/Regularory AstraZeneca Nordic-Baltic
Medical Nordic-Baltic, AstraZeneca Nordic-Baltic, Arne Jacobsens Allé 13 DK-2300 Copenhagen S Den

13 Approvals

We have reviewed this study protocol (ER-9502 Version 1.0, dated 02 April 2015) and agree to its terms by signing it.

Principal investigator:

Signature

Date

Tuire Prami

EPID Research, Metsänneidonkuja 12, FI-02130 Espoo

Medical experts of the scientific committee:

Signature

Date

Juhani Airaksinen

Turku University Hospital, P.O. Box 52 FI-20521 Turku

Signature

Date

Eeva Reissell

THL, P.O. Box 30 FI-00271 Helsinki

Signature

Date

Ville Kytö

Turku University Hospital, P.O. Box 52 FI-20521 Turku

Turku, Finland 10/4/2015

On behalf of the sponsor:

Signature

Date

Susanne Skovgaard Nickelsen, MD VP Medical/Regularory AstraZeneca Nordic-Baltic

Medical Nordic-Baltic, AstraZeneca Nordic-Baltic, Arne Jacobsens Allé 13 DK-2300 Copenhagen S Denmark

13 Approvals

We have reviewed this study protocol (ER-9502 Version 1.0, dated 02 April 2015) and agree to its terms by signing it.

Principal investigator:

Signature

Date

Tuire Prami

EPID Research, Metsänneidonkuja 12, FI-02130 Espoo

Medical experts of the scientific committee:

Signature

Date

Juhani Airaksinen

Turku University Hospital, P.O. Box 52 FI-20521 Turku

Signature

Date

Eeva Reissell

THL, P.O. Box 30 FI-00271 Helsinki

Signature

Date

Ville Kytö

Turku University Hospital, P.O. Box 52 FI-20521 Turku

On behalf of the sponsor:



8. April 2015

Signature

Date

Susanne Skovgaard Nickelsen, MD VP Medical/Regularory AstraZeneca Nordic-Baltic

Medical Nordic-Baltic, AstraZeneca Nordic-Baltic, Arne Jacobsens Allé 13 DK-2300 Copenhagen S Denmark